Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- NBI Files for Micardis, Amlodipine, Diuretic Triple Combination Agents
August 18, 2015
- ASCO Immunotherapy Roundup - 7: Patient Group Hails Dawn of New Cancer Treatment Era
August 14, 2015
- Otsuka’s US Subsidiary Wins Patent Lawsuit over PBA Treatment
August 14, 2015
- Japan’s Diabetes Market to Exceed 600 Billion Yen in 2023: Fuji Keizai
August 14, 2015
- Kyowa Kirin Looks to Derive 40% of Sales Overseas by 2020, Split from Holdings Firm Won’t Happen: Pres.
August 13, 2015
- Hospira Japan’s Generic Oxaliplatin Approved for Gastric Cancer
August 13, 2015
- Ethical Drug Sales Up 9.8% in June: Crecon Report
August 13, 2015
- INCJ Invests 600 Million Yen in Drug Discovery Venture Founded by Tokyo Medical and Dental Univ.
August 12, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- Quintiles to Set Up Unit for Medical Devices and Regenerative Medicines
August 12, 2015
- Biogen Japan Expects Continued Growth Past 2020 through Major New Drugs
August 11, 2015
- Long-Acting Injectable Version of Abilify Entering Accelerated Growth Phase: Pres. Higuchi of Otsuka Holdings
August 11, 2015
- Sublingual Immunotherapy Tablet for Pollinosis Shows Efficacy in PII/PIII Study in Japan: Torii
August 11, 2015
- Denki Kagaku Kogyo to Acquire Germany’s Biopharma Icon Genetics
August 11, 2015
- Drug Wholesalers Suffer 1st Sales Drop since 1997
August 10, 2015
- Sumitomo Dainippon Will Be Able to Cover the Loss of Long-Listed Drug Sales: President
August 10, 2015
- Pharmaceutical Sales Down 2.4% in 1st Half Due to Loss of Patent Protection for Abilify in US: Otsuka Holdings
August 10, 2015
- Sosei’s UK Subsidiary, AZ Partner for Development of Cancer Immunotherapies
August 10, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- Sanofi Files NDA for Hypercholesterolemia Treatment Alirocumab in Japan
August 7, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…